1 / 53

Pulmonary Function Tests

Pulmonary Function Tests. Ghassan Jamaleddine, M.D. American University of Beirut. Use of PFT’s. Evaluating breathlessness Initial evaluation of patient with known respiratory disease Following the course of a respiratory disease Pre-operative assessment Disability evaluation

tale
Download Presentation

Pulmonary Function Tests

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pulmonary Function Tests Ghassan Jamaleddine, M.D. American University of Beirut

  2. Use of PFT’s • Evaluating breathlessness • Initial evaluation of patient with known respiratory disease • Following the course of a respiratory disease • Pre-operative assessment • Disability evaluation • Screening of subclinical disease

  3. Disadvantages of PFT’s • Patient’s cooperation and an informed technician are required • Measures the lung and chest as a unit • Evaluates disease at only one point in time • Errors in programs of computer driven automated equipment

  4. Routine PFT’s • Spirometry with or without Flow Volume loop • Static lung volumes • Single Breath Diffusing Capacity

  5. Spirometry • Forced vital capacity • Forced Expiratory Volume in one second (FEV1) • Percent Expired (FEV1/FVC or FEV1%) • Forced Mid-Expiratory Flow (FEF 25-75) or Maximal Mid-Expiratory Flow (MMEF or MMF) • Peak or Maximal Expiratory Flow Rate (PEF or MEFR)

  6. Obstructive Vent defect FVC reduced or Normal FEV1 reduced FEV1/FVC is reduced Example: Asthma, COPD Restrictive Vent defect FVC reduced FEV1 normal or reduced FEV1/FVC is increased Example: pulmonary fibrosis, pleural effusion, neuromuscular Pattern of defects seen on PFT’s

  7. P1V1 = P2 (V1-Δ V)

  8. Lung Volumes • Functional Residual Capacity • Expiratory Reserve Volume • Residual Volume • Inspiratory Capacity • Total Lung Capacity • Vital Capacity

  9. FLOW VOLUME LOOP

  10. Diffusion • Transfer of a gas across a tissue sheet, governed by Fick’s law • Rate of Transfer = A D x P/T

  11. Diffusion Capacity (measurement) A D x (P1- P2) T AD/T = Diffusion constante Rate of transfer (CO) = Vco = Dlco x (P1-P2) Dlco = Vco/ PA –Pa = Vco/ PA 25 ml/min/mmHg

  12. Diffusing Capacity • Influenced by: • Changes in alveolar-capillary membrane • Pulmonary circulation • Ventilation perfusion matching • Hemoglobin concentration

  13. Diffusion Capacity • Very important in • Interstitial lung disease • Drug induced lung injury • Reduced in Emphysema because of destruction of alveolar units

  14. PFT Patterns in Disease PFT results are best interpreted with knowledge of the patients history, physical exam and occasionally chest X-ray.

  15. Case 1 • 14 year old boy came to ER with increasing shortness of breath • History of asthma since age of 2-3 • Maintained on ICS and Beta2 agonists • Followed by Family physician, past year frequent attacks, several courses of antibiotics and systemic corticosteroids

  16. Case 1 (cont’d) • In ER started on iv steroids and inhaled Beta 2 agonists, no improvement, admitted • No history of atopy, no nasal nor GI symptoms, no family history of asthma • Exam: decrease breath sounds • Admitted

  17. Case 1 (cont’d) • CXR, CBC, chemistry non revealing • After 2 days of treatment with steroids and inhaled bronchodilators there was no improvement in symptoms • Noticed faint voice and tachypnea on minimal exercise • PFT obtained

  18. Case PFT’s • FVC 93%, FEV1 45%, FEV1/FVC 41% • TLC 90%, RV 90%, DLCO 100% • ?????

  19. Case 1(cont’d) • FOB: subglottic stenosis (? Congenital) • Tracheostomy followed by reconstructive surgery • Total recovery, no more asthma treatment

  20. Case 2 • 32 year old man presented with 2 months history of increasing shortness of breath • Married, non-smoker, bank employee, no history of asthma • No other symptoms • Shortness of breath increasing before presentation • Seen by multiple physicians, given a number of antibiotics, bronchodilators, aminophylline

  21. Case 2 (Cont’d) • Exam: BP 120/80, RR 18, P100, BMI 29, afebrile, chest: clear… rest of exam was normal • ER: ABG’s normal, CXR: normal, CT angio: normal, neuro consult (fellow): no neuro problem • Patient reassured by the team

  22. Case 2 (cont’d) • Spirometry obtained: • FVC 50% • FEV1 55% • FEV1/FVC 80% • MVV 20% • ????

  23. Case 2 (cont’d) • Neurology attending reconsulted • EMG: Myasthenia Gravis • Diagnosis suspected from FVC and MVV • Neuromuscular illness

  24. Case 3 • A 60 year old man with history of ex-smoking, history of seasonal colds, admitted for hernia operation • Pulmonary consulted for pre-op clearance because of obesity • The patient denied pulmonary complaints, but his wife disclosed that he has a chronic cough

  25. Case 3 Obstructed defect

  26. Case 3

  27. Pre-operative screening • Patients with known pulmonary illness or symptoms • Overweight patients • Patients undergoing surgery in the chest or near the diaphragm

  28. Case 4 • A 65 year old man non-smoker, lawyer, admitted for elective Lap Chole. Reports long history of mild cough, and dyspnea on exertion • Physical exam: bibasilar dry crackles (velcrow), clubbing of the fingers

  29. Case 4 Restricted defect

  30. Case 4 • TLC 60% • RV 40% • DLCO 40% • HRCT

  31. Case 4

  32. Case 5 • 68 year old man with progressive dyspnea of one year duration, ex-smoker, no cough, no wheezing, no orthopnea… • History of CAD, SVT post angioplasty on multiple medication • EF% 55 • Meds: Plavix, beta one blocker, diuretics, cordarone, ARB,

  33. Case 5 • FVC 50% • FEV1 55% • FEV1/FVC 85% • TLC 70% • DLCO 50%

  34. Case 5 • PFT’s: Major drop in FVC and DLCO compared to the PFT done 2 years earlier • HRCT of chest: Increased markings over the bases, with areas of increased enhancement…. Consistent with Amiodarone toxicity

  35. Follow up patients • Connective Tissue diseases (e.g. scleroderma) • Patients on Therapy that might affect the pulmonary system • Neuromuscular diseases

More Related